A Phase 2 Multicenter, Open-label, Single-arm Study of KTE-C19 in Japanese Patients with Refractory or Relapsed Large B Cell Lymphoma

Trial Profile

A Phase 2 Multicenter, Open-label, Single-arm Study of KTE-C19 in Japanese Patients with Refractory or Relapsed Large B Cell Lymphoma

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs Axicabtagene ciloleucel (Primary)
  • Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Therapeutic Use
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 06 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top